A Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer

• Status: Unknown status
• Trial end date: 2016-12-01
• Target enrollment: 0
• Participant gender: All

Summary

SHIVA is a proof of concept randomized phase II trial which compares two treatment strategies for patients with refractory cancer.

From a tumor biopsy, a molecular profile of the disease is established (mutations, amplifications, hormone receptor status). If a molecular abnormality is identified for which an approved targeted agent is available, patients are randomized randomized between two arms:

• Targeted therapy based on the molecular profile

• Conventional therapy based on investigator's choice.

A cross-over is proposed at disease progression.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Institut Curie
• Treatments: Dasatinib; Erlotinib Hydrochloride; Everolimus; Imatinib Mesylate; Lapatinib; Letrozole; Sirolimus; Sorafenib; Tamoxifen; Trastuzumab; Vemurafenib

Criteria

Inclusion Criteria:

1. Patient with recurrent/metastatic solid tumor who failed or are not candidate for treatments usually proposed in first intentions and for whom a prospective clinical trial has been indicated in a tumor board

2. ECOG performance status of 0 or 1

3. Biopsiable disease (tumor biopsy mandatory for tumor profiling). The biopsy can be performed when patients are being treated with standard therapy for their recurrent/metastatic cancer if it is not planned to treat them with molecularly targeted agents in the future.

4. Measurable disease

5. Adequate renal function defined by a serum creatinine <1.5xUNL (upper normal limit)

6. Adequate liver function test defined by SGOT & SGPT <3xUNL (5xUNL in case of liver metastases), and bilirubin level <1.5xUNL

7. Adequate bone marrow function defined by platelets >100,000/mm3, hemoglobin >10 g/dL, and neutrophils >1,000/mm3

8. Patients must be affiliated to the French Social Security System

9. Signed informed consent

10. For female of child-bearing potential: a negative pregnancy test <72 hours before starting study treatment is required. If sexually active, female of childbearing potential must use "highly effective" methods of contraception for the study duration and for 3 months following the last treatment

11. For male of reproductive potential: any sexually active male patient must use a condom while on study treatment and for 3 months following the last treatment

12. Agreement to send the CD-ROMs of imaging for central review

Exclusion Criteria:

1. Patients who have only bone and/or brain metastases

2. Patients whose brain metastases have not been controlled for >3 months

3. Patient participating in another clinical trial with an experimental drug

4. Patients who are candidate to receive a molecularly targeted agent that is approved for their disease

5. Anticoagulation with anti-vitamin K (Low Molecular Weight Heparin [LMWH] is allowed)

6. Patients with other concurrent severe and/or uncontrolled medical disease which could compromise participation in the study, including uncontrolled diabetes, cardiac disease, uncontrolled hypertension, congestive cardiac failure, ventricular arrhythmias, active ischemic heart disease, myocardial infection within one year, chronic liver or renal disease, active gastrointestinal tract ulceration, severely impaired lung function

7. Pregnant and/or breastfeeding women

8. Individually deprived of liberty or placed under the authority of a tutor

9. Patients with any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule

10. Known HIV, HBV, or HCV infection

Eligibility criteria for the randomized part :

1. Identification of tumor molecular abnormalities for which the Therapeutic Decision Committee (TDC) recommends a molecularly targeted therapy available in the context of the trial (even if the molecular profile is incomplete)

2. Therapy recommended by the TDC is not approved for the patient's disease

3. ECOG performance status of 0 or 1

4. Adequate renal function defined by a serum creatinine <1.5xUNL

5. Adequate liver function tests defined by SGOT & SGPT <3xUNL (5xUNL in case of liver metastases), and bilirubin level <1.5xUNL

6. Adequate bone marrow function defined by platelets >100,000/mm3, hemoglobin >8 g/dL, and neutrophils >1,000/mm3

7. Albumin, LDH and number of metastatic sites have been documented (in order to determine the RMH prognostic score)

8. LVEF >50%

9. QTc <480 ms on ECG